Andere Sprachen Guard Therapeutics International AB

Aktien

A3E2EN

SE0021181559

GUARD

Verzögert Nasdaq Stockholm Andere Börsenplätze 09:50:10 01.07.2024			% 5 Tage	% 1. Jan.
30.6 ^SEK	+4.08%		+4.08%	-14.53%

27.05.	Guard Therapeutics gibt bekannt, dass die wissenschaftliche Zeitschrift American Journal of Physiology ? Renal Physiology veröffentlicht Artikel, der wichtige präklinische Ergebnisse des klinischen Wirkstoffkandidaten RMC-035 zusammenfasst	CI
08.05.	Guard Therapeutics International AB (publ) meldet Ergebniszahlen für das erste Quartal zum 31. März 2024	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Guard Therapeutics carries out a directed share issue of approximately SEK 60 million and intends to carry out a repair issue	17.06.
Guard Therapeutics research published in American Journal of Physiology – Renal Physiology	27.05.
Guard Therapeutics Announces Scientific Journal American Journal of Physiology ? Renal Physiology Publishes Article Summarizing Important Preclinical Results of Its Clinical Drug Candidate RMC-035	27.05.
Guard Therapeutics International AB Reports Earnings Results for the First Quarter Ended March 31, 2024	08.05.
Guard Therapeutics receives its first regulatory approval for the phase 2b study POINTER	15.04.
Guard Therapeutics Receives First Regulatory Approval for the Phase 2b Study POINTER	15.04.
Guard Therapeutics International AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	21.02.
Guard Therapeutics International AB Reports Earnings Results for the Full Year Ended December 31, 2023	21.02.
Guard Therapeutics presented development strategy and new preclinical results at R&D Update	31.01.
Guard Therapeutics Presents Development Strategy and New Preclinical Results at R&D Update	31.01.
Invitation to Guard Therapeutics’ R&D Update on January 30	18.01.
US FDA Gives Positive Feedback on Guard Therapeutics’ RMC-035 Development Plan; Stock Plunges	15.01.
FDA provides positive feedback to Guard Therapeutics regarding the continued development plan for RMC-035	15.01.
Guard Therapeutics International AB Announces Fda Provides Positive Feedback to Guard Therapeutics Regarding the Continued Development Plan for RMC-035	15.01.
Guard Therapeutics presents the Nomination Committee for 2024	07.12.
Guard Therapeutics International AB Appoints Nomination Committee for 2024	07.12.
Guard Therapeutics International AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10.11.
Guard Therapeutics presents late breaking clinical trial abstract at ASN Kidney Week 2023	23.10.23
Guard Therapeutics provides more information on the development strategy for RMC-035	28.09.23
Guard Therapeutics International AB Provides More Information on the Development Strategy for RMC-035	28.09.23

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Guard Therapeutics International AB

Aktien

A3E2EN

SE0021181559

GUARD

Andere Sprachen

Filter